A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.

Part of paid clinical trials in Cincinnati, Ohio.

Sponsor
The Christ Hospital
Study ID
NCT07207395
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Lung Cancer (NSCLC)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • JBI-802 — DRUG
    LSD1/HDAC6 Inhibitor
  • Pembrolizumab — DRUG
    PD-1

Study Details

The purpose of this study is to determine the overall safety and tolerability of JBI-802 as single agent and in combination with Pembrolizumab.

Key Dates

Start date
Apr 29, 2025
Status verified
Oct 2025
Primary completion
Oct 31, 2027
Completion
Oct 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Monotherapy
    JBI-082 Single Agent
  • Experimental: Combination
    JBI-802 plus Pembrolizumab

Primary Outcome Measure

Incidence of Adverse Events [ Time Frame: Up to 28 days after last dose of study drug ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The Christ HospitalCincinnatiOhio45219
Abby Reed
[email protected]
513-585-0844
Alexander Starodub, MD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cincinnati, OH

By research site
The Christ Hospital· Cincinnati, OH

Related Studies